Viking Therapeutics (VKTX) has seen a notable 5.61% increase in its stock as it approaches a pivotal phase in its clinical development. The biotech firm, which has been public for nearly 11 years, is currently conducting phase 3 studies on its leading candidate, VK2735, a dual GLP-1/GIP agonist aimed at weight management. With results from these trials expected within the next 18 months, the stakes are high for both the company and its investors.
The weight-loss market is projected to exceed $100 billion in the coming decade, presenting substantial revenue potential for successful entrants. Analysts estimate VK2735 could generate up to $21.6 billion at peak sales, rivaling established products like Eli Lilly’s Zepbound. However, Viking must not only demonstrate competitive efficacy but also navigate a landscape filled with increasing competition and regulatory hurdles.
For market professionals, the key takeaway is the high-risk, high-reward nature of investing in Viking Therapeutics. While the potential for significant returns exists, the company must overcome substantial challenges to secure its place in the competitive weight-loss market.
Source: fool.com